QT Prolongation and Arrhythmias in Cancer Therapy: A Narrative Review of Mechanistic and Clinical Studies. (PubMed, Cardiovasc Toxicol) - May 24, 2026 - "High-risk agents, including arsenic trioxide, vandetanib, nilotinib, sunitinib, and ribociclib, are contrasted with lower-risk alternatives and QT-sparing strategies...Among supportive medications, fluoroquinolones, azole antifungals, and certain antiemetics frequently interact with QT-active anticancer agents, whereas beta-lactams, echinocandins, isavuconazole, and palonosetron may represent safer alternatives...Finally, we highlight system-level measures, such as drug interaction stewardship, standardized discharge communication, and clinician education, to shift cardio-oncology practice from reactive arrhythmia management toward anticipatory prevention. This integrative synthesis aims to preserve oncologic efficacy while mitigating arrhythmic risk in modern cancer care."
Journal • Review • Cardiovascular • Oncology
|
|
Andrew Greek; Eric Sanji; Kayode E Ogunniyi; Oghenevwede Anderson Okuma; Samuel Abiola Ayedun; Trie Arni Djunadi; Victor Onyenokwe
|